<table>
<thead>
<tr>
<th>Title</th>
<th>BROADLY CROSS-REACTIVE NEUTRALIZING ANTIBODIES AGAINST HUMAN IMMUNODEFICIENCY VIRUS SELECTED BY ENV-CD4-CO-RECEPTOR COMPLEXES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inventor(s)</td>
<td>DIMITROV DIMITER S; MOULARD MAXIME; XIAO XIADONG; SHU YUUEI; PHOGAT SANJAY K; ZHANG MEI-YUN; BURTON DENNIS</td>
</tr>
<tr>
<td>Issued Date</td>
<td>2007</td>
</tr>
<tr>
<td>URL</td>
<td><a href="http://hdl.handle.net/10722/194058">http://hdl.handle.net/10722/194058</a></td>
</tr>
<tr>
<td>Rights</td>
<td>This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.</td>
</tr>
</tbody>
</table>
BROADLY CROSS-REACTIVE NEUTRALIZING ANTIBODIES AGAINST HUMAN IMMUNODEFICIENCY VIRUS SELECTED BY ENV-CD4-CO-RECEPTOR COMPLEXES

Related U.S. Application Data

Division of application No. 10/492,729, filed on May 5, 2004, now Pat. No. 7,223,844, filed as 371 of international application No. PCT/US02/33165, filed on Oct. 16, 2002.

Provisional application No. 60/329,709, filed on Oct. 16, 2001.

Publication Classification

Int. Cl. A61K 39/395 (2006.01)
C12N 5/06 (2006.01)
C12N 5/16 (2006.01)

U.S. Cl. ........................................ 424/130.1; 435/345

ABSTRACT

The present invention relates to antibodies and antibody fragments that specifically bind a CD4-inducible HIV gp120 epitope that is enhanced by binding a co-receptor for HIV, such as CCR5 or CXCR4, and pharmaceutical compositions comprising the antibodies or antibody fragments. The invention also features nucleic acids encoding the antibodies or antibody fragments, pharmaceutical compositions comprising the nucleic acids encoding the antibodies or antibody fragments, vectors comprising the nucleic acids, and cells comprising the vectors. The invention further features methods of identifying antibodies or antibody fragments with broadly neutralizing activity against HIV. The invention also features methods of inhibiting HIV entry into cells and methods of inhibiting replication of HIV in mammals, using the antibodies and nucleic acids of the invention.

X5 Heavy chain

```
X5 Heavy chain

FAE Signal

HEVLLFTAAAGLLALLAAGPANAHERQVQLLEQSCGABF

CDR1

PSGSPQSVKCAEEDGTTFSKHYPFSNPVRQAPGHCLENH

CDR2

GIPIPGTSWTAQFHRGVTFTDQATSTMELMLT

CDR3

GDDTAVYCRDQVFQDNEHODSDFGOSORGFWFDQ

FR4

GTVTPSSSLGOTOSYICRTVXETPDSYCTKE

FR1

KDFPPFPVYVSNNSGALTSGVHTPAYLTQZSGG

DXTS
```
FIGURE 1
FIGURE 2
FIGURE 4
**FIGURE 5**

A

HOS-CD4-CGR5 cells

- JFRL
- B31
- 89.6

X5 ng/ml

Luciferase activity (%)

B

HOS-CD4-CXCR4 cells

- NL-43
- 89.6

X5 ng/ml

Luciferase activity (%)

FIGURE 5
FIGURE 6
## X5 Light Chain

**Complementing signal**

<table>
<thead>
<tr>
<th>CDR1</th>
<th>FR1</th>
</tr>
</thead>
<tbody>
<tr>
<td>MKKTAAIAVAALAGFATVACRQLVEQTSPEGTLSLVS</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CDR2</th>
<th>FR2</th>
</tr>
</thead>
<tbody>
<tr>
<td>GERTLSRCASQSVSSTISSLAWYQQKPGQAPRLLITYGA</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CDR3</th>
<th>JK</th>
<th>CL</th>
</tr>
</thead>
<tbody>
<tr>
<td>STRATGIPDRFSGSGSTSFTTLTIGLDFEDLAVYYCQ</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CDR3</th>
<th>JK</th>
<th>CL</th>
</tr>
</thead>
<tbody>
<tr>
<td>QYGTSPTYFGQQGTKLEIKRTVDAPSVFFIFPPSDEQLKS</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CDR3</th>
<th>JK</th>
<th>CL</th>
</tr>
</thead>
<tbody>
<tr>
<td>GTASVVCLLNYPFREAKVQKWIDNALQSGNSQESV</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CDR3</th>
<th>JK</th>
<th>CL</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEHDSRSDSTYSGTLLTLSKADYKHKVYACEVTHQG</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CDR3</th>
<th>JK</th>
<th>CL</th>
</tr>
</thead>
<tbody>
<tr>
<td>LSSPVTKSFNRGEC</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**FIGURE 7**
**X5 Heavy chain**

**PalB Signal**

```
MKYLLPTAARGCLMLLLAAQPADMAEVEQLLSEQSGAEVK
```

**CDR1**

```
PGSSVQVSCKASGGTFPSMYGFNNVQRAPGRHGLEWMG
```

**CDR2**

```
GIYPIFGTSNYAQKFRGRVTFTADQATSTAYMELTNLR
```

**CDR3**

```
SDDTAVYCARDFGPDWEDGDSYGSGRGGFFDFWGQ
```

**FR1**

```

```

**FR2**

```

```

**FR3**

```

```

**FR4**

```

```

**CH1**

```
GTLVTVSASSATKGPSVFPPLAPSSKSTSGTAAALGCLV

```

**PG**

```

```

**DKTS**

```
KDYPFPEVPVTSMNGALTSGVHTFPAVLQSSGLYSLS

```

**SVTVPSSSLGTQTYICNVNHKPSNTKVDDKKVEPKSC**

**FIGURE 8**
BROADLY CROSS-REACTIVE NEUTRALIZING ANTIBODIES AGAINST HUMAN IMMUNODEFICIENCY VIRUS SELECTED BY ENV-CD4-CO-RECEPTOR COMPLEXES

STATEMENT OF FEDERALLY SPONSORED RESEARCH

[0001] This invention was made with government support under Contract No. A33292 by the National Institutes of Health. The government of the United States of America has certain rights in the invention.

FIELD OF THE INVENTION

[0002] This invention generally relates to broadly neutralizing antibodies against Human Immunodeficiency Virus, and methods of making and using the same.

BACKGROUND OF THE INVENTION

[0003] The Human Immunodeficiency Virus (HIV) is the causative agent of Acquired Immunodeficiency Syndrome (AIDS). HIV entry into cells involves formation of a complex between the HIV envelope glycoprotein (Env), which consists of a complex containing the HIV glycoproteins gp120 and gp41; gp120-gp41, a cell-surface receptor (CD4), and a cell-surface co-receptor (e.g., the chemokine receptor CCR5 or CXCR4). Binding of Env to CD4 and either co-receptor initiates a series of conformational changes that are at the heart of the fusion machinery leading to viral entry into the target cell. Therefore, efforts to develop a vaccine for the prevention and/or treatment of HIV infection have focused upon the development of neutralizing antibodies that specifically bind to Env. However, the extensive variation of Env in the numerous isolates of HIV so far identified presents a major obstacle in designing an effective immunogen for the isolation of antibodies with broadly neutralizing activity against multiple HIV isolates.

[0004] Currently there are only three well-characterized monoclonal antibodies (mAbs) with broadly neutralizing activity: the anti-gp120 mAbs b12 (Burton et al. Science 266:1024-1027, 1994) and 2G12 (Trkola et al. J. Virol. 70:1100-1108, 1996), and the anti-gp41 mAb 2F5 (Conley et al. Proc. Natl. Acad. Sci. U.S.A. 91:3348-3352, 1994). Given the ever-increasing number of people infected with HIV, there is a need in the art for additional antibodies with broadly neutralizing activity against HIV, which can be used as passive immunotherapy or passive immunoprophylaxis to treat, ameliorate, inhibit, or prevent HIV infections in individuals who have, or who at risk for developing, such infections. Furthermore, there is a need in the art for new strategies by which to identify and/or isolate such broadly neutralizing anti-HIV antibodies.

SUMMARY OF THE INVENTION

[0005] We have discovered that purified complexes containing HIV Env together with the cell-surface HIV receptor CD4 and an HIV co-receptor, e.g., CCR5 or CXCR4, can be used to identify and isolate antibodies, and active fragments thereof, which display broadly neutralizing activity against multiple genetic subtypes of HIV. Such antibodies can be used as inhibitors of HIV infection and for development of HIV vaccines.

[0006] In a first aspect, the invention relates to an isolated antibody or antibody fragment that specifically binds a CD4-inducible epitope on Human Immunodeficiency Virus (HIV) Env that is enhanced by the binding of Env to a co-receptor for HIV, wherein the CD4-inducible epitope is distinct from the HIV co-receptor binding site on gp120.

[0007] In one embodiment of the first aspect of the invention, the antibody or antibody fragment is selected by virtue of its ability to specifically bind to a CD4-inducible epitope on HIV Env that is enhanced by binding a co-receptor for HIV.

[0008] In a second aspect, the invention relates to an isolated antibody or antibody fragment that is selected by virtue of its ability to specifically bind to a CD4-inducible epitope on Human Immunodeficiency Virus (HIV) Env that is enhanced by the binding of Env to a co-receptor for HIV, and wherein the CD4-inducible epitope is distinct from the HIV co-receptor binding site on gp120.

[0009] In various embodiments of the first and second aspects of the invention, the epitope can be on gp120, on gp41, or on gp120-gp41 (Env).

[0010] In a third aspect, the invention relates to an isolated antibody or antibody fragment that is selected by virtue of its ability to specifically bind to a complex comprising HIV gp120, CD4, and a co-receptor for HIV. In one embodiment of the third aspect of the invention, the complex also comprises gp41.

[0011] In various embodiments of the first, second, and third aspects of the invention, the HIV co-receptor can be CCR5 or CXCR4; the isolated antibody or antibody fragment can have broadly neutralizing activity against HIV, e.g., HIV-1; the isolated antibody or antibody fragment can be monoclonal; the isolated antibody or antibody fragment can be human or humanized, and/or the isolated antibody or antibody fragment can be isolated from a phage display library.

[0012] In other embodiments of the first, second, and third aspects of the invention, the antibody or antibody fragment can comprise the heavy chain of the Fab fragment X5 (SEQ ID NO: 3), the light chain of the Fab fragment X5 (SEQ ID NO: 2), or both chains of X5.

[0013] In still other embodiments of the first, second, and third aspects of the invention, the isolated antibody or antibody fragment can comprise the CDR3 region (SEQ ID NO: 5) of the heavy chain of the Fab fragment X5 and/or the CDR3 region (SEQ ID NO: 8) of the light chain of the Fab fragment X5. The antibody or antibody fragment can also comprise any of the other CDR and/or FR regions found in the heavy or light chain of antibody Fab fragment X5, in any combination.

[0014] In yet other embodiments of the first, second, and third aspects of the invention, a fusion polypeptide comprising a heavy chain or light chain of the antibody or antibody fragment can comprise a soluble CD4 (sCD4) domain. Such a polypeptide can further comprise an amino acid sequence corresponding to that of the peptide T20, which is a synthetic peptide derived from the HIV gp41 amino acid sequence.

[0015] In a fourth aspect, the invention relates to an isolated polypeptide comprising the heavy chain of antibody Fab fragment X5 (SEQ ID NO: 3).
In a fifth aspect, the invention relates to an isolated polypeptide comprising the light chain of antibody Fab fragment X5 (SEQ ID NO: 2).

In a sixth aspect, the invention relates to an isolated polypeptide comprising the CDR3 region (SEQ ID NO: 5) of the heavy chain of antibody Fab fragment X5.

In a seventh aspect, the invention relates to an isolated polypeptide comprising the CDR3 region (SEQ ID NO: 8) of the light chain of antibody Fab fragment X5.

In an eighth aspect, the invention relates to an isolated polypeptide comprising the CDR3 region (SEQ ID NO: 5) of the heavy chain of antibody Fab fragment X5 and the CDR3 region (SEQ ID NO: 8) of the light chain of antibody Fab fragment X5. For example, the polypeptide can be a single chain antibody or a single chain antibody fragment, such as a single chain variable fragment (ScFv).

In a ninth aspect, the invention relates to an antibody or antibody fragment that is an amino acid sequence variant of the Fab fragment X5, wherein the sequence variant of X5 comprises at least one amino acid substitution in the heavy chain or light chain of X5, wherein the sequence variant of X5 binds a complex comprising gp120, CD4, and an HIV-co-receptor with an affinity that is about equal to or greater than the affinity by which X5 binds the comprising gp120, CD4, and an HIV-co-receptor.

In one embodiment of the ninth aspect of the invention, the sequence variant of X5 has broadly neutralizing activity against HIV-1. In another embodiment, the amino acid substitution is in the CDR3 region of the heavy chain and/or light chain of X5. The amino acid substitution can also be in any other region of the heavy or light chains, e.g., in any of the CDR, FR, or CH1 regions; for example, the amino acid substitution can be in CH1, and the sequence variant of X5 can comprise SEQ ID NO: 11.

In another embodiment of the ninth aspect of the invention, the sequence variant of X5 is selected by virtue of its ability to specifically bind to a complex comprising HIV gp120, CD4, and a co-receptor for HIV. In another embodiment, the sequence variant of X5 is selected by virtue of its ability to specifically bind to a CD4-inducible epitope on HIV Env that is enhanced by binding a co-receptor for HIV.

In a tenth aspect, the invention relates to an isolated polypeptide comprising an amino acid sequence variant of a CDR3 region of antibody Fab fragment X5, wherein an antibody or antibody fragment comprising the amino acid sequence variant of the CDR3 region of X5 binds HIV gp120 with an affinity that is about equal to or greater than to the affinity by which X5 binds gp120. The CDR3 region may be from the heavy chain or the light chain of antibody X5.

In one embodiment of the ninth and tenth aspects of the invention, the amino acid sequence variant is selected by virtue of its equivalent or increased affinity for gp120 relative to the affinity of X5 for gp120.

In an eleventh aspect, the invention relates to an isolated nucleic acid that encodes SEQ ID NO: 3.

In a twelfth aspect, the invention relates to an isolated nucleic acid that encodes SEQ ID NO: 2.

In a thirteenth aspect, the invention relates to an isolated nucleic acid that encodes SEQ ID NO: 5.

In a fourteenth aspect, the invention relates to an isolated nucleic acid that encodes SEQ ID NO: 8.

In a fifteenth aspect, the invention relates to an isolated nucleic acid that encodes an antibody or antibody fragment comprising the CDR3 region (SEQ ID NO: 5) of the heavy chain of antibody Fab fragment X5 and the CDR3 region (SEQ ID NO: 8) of the light chain of antibody Fab fragment X5.

In a sixteenth aspect, the invention relates to an isolated nucleic acid that encodes an antibody or antibody fragment comprising the heavy chain of antibody Fab fragment X5 (SEQ ID NO: 3) and the light chain of antibody Fab fragment X5 (SEQ ID NO: 2). For example, the isolated nucleic acid can comprise the nucleotide sequence set forth in SEQ ID NO: 4.

In a seventeenth aspect, the invention relates to an isolated vector comprising the isolated nucleic acid of aspects eleven through sixteen above. The vector can be, for example, an expression vector for expression of the peptide or polypeptide encoded by the isolated nucleic acid.

In an eighteenth aspect, the invention relates to an isolated cell comprising the isolated vector of the seventeenth aspect of the invention. The cell can be a prokaryotic or an eukaryotic cell.

In a nineteenth aspect, the invention relates to a pharmaceutical composition comprising the isolated antibody or antibody fragment of the first three aspects and the ninth aspect of the invention, and a pharmaceutically acceptable carrier. The pharmaceutical composition can further comprise soluble CD4.

In a twentieth aspect, the invention relates to a pharmaceutical composition comprising a nucleic acid that encodes the isolated antibody or antibody fragment of the first three aspects and the ninth aspect of the invention, and a pharmaceutically acceptable carrier. In one embodiment of the twentieth aspect of the invention, the nucleic acid is within an expression vector.

In a twenty-first aspect, the invention relates to a method of selecting an antibody or antibody fragment with broadly neutralizing activity against HIV, comprising detecting an antibody or antibody fragment that specifically binds a CD4-inducible epitope on HIV Env that is enhanced by the binding of Env to a co-receptor for HIV, wherein the CD4-inducible epitope is distinct from the HIV co-receptor binding site on gp120. For example, the antibody or antibody fragment can be selected by virtue of its binding to a complex comprising HIV gp120, CD4, and a co-receptor for HIV.

In a twenty-second aspect, the invention relates to an antibody produced by the method of the twenty-first aspect of the invention.

In a twenty-third aspect, the invention relates to a method of inhibiting entry of HIV into a cell, comprising administering to the cell an effective amount of an isolated antibody or antibody fragment that specifically binds a CD4-inducible epitope on HIV Env that is enhanced by the binding of Env to a co-receptor for HIV, wherein the
CD4-inducible epitope is distinct from the HIV co-receptor binding site on gp120, thereby inhibiting entry of HIV into the cell.

[0038] In various embodiments of the twenty-third aspect of the invention, the cell can be any cell susceptible to HIV infection, e.g., but not limited to, a T cell, a B cell, a monocyte, a macrophage, or a microglial cell. In another embodiment of the twenty-third aspect of the invention, the cell is within a mammal that is susceptible to infection by HIV and the isolated antibody or antibody fragment is administered to the mammal.

[0039] In a twenty-fourth aspect, the invention relates to a method of inhibiting replication of HIV in a mammal that is susceptible to HIV infection, comprising administering to the mammal an effective amount of an isolated antibody or antibody fragment that specifically binds a CD4-inducible epitope on HIV Env that is enhanced by the binding of Env to a co-receptor for HIV, wherein the CD4-inducible epitope is distinct from the HIV co-receptor binding site on gp120, thereby inhibiting replication of HIV in the mammal.

[0040] In various embodiments of the twenty-third and twenty-fourth aspects of the invention, the isolated antibody or antibody fragment is administered to the mammal by administering a nucleic acid encoding the isolated antibody or antibody fragment to the mammal.

[0041] In other embodiments of the twenty-third and twenty-fourth aspects of the invention the mammal is a primate, for example, a human or a non-human primate.

[0042] In all of the above embodiments of the invention, the HIV can be HIV-1 or HIV-2.

[0043] In all of the above embodiments of the invention, the co-receptor can be, e.g., CCR5 or CXCR4.

[0044] Additional advantages of the invention will be set forth in part in the description which follows, and in part will be apparent from the description, or may be learned by practice of the invention. The advantages of the invention will be realized and attained by means of the elements and combinations particularly pointed out in the appended claims. It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention as claimed.

Definitions

[0045] In this specification and in the claims which follow, reference will be made to a number of terms which shall be defined to have the following meanings. It is to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting.

[0046] By “specifically binds”, “specifically reacts with”, “specifically interacts with”, and similar terms is meant that an anti-HIV antibody of the invention physically associates with its target molecule (e.g., gp120 and/or gp41 of HIV Env) to inhibit HIV entry into a cell and/or to inhibit or prevent HIV replication in a mammal. Preferably, the antibody does not substantially physically associate with other molecules.

[0047] By a “broadly neutralizing” antibody against HIV, and similar terms, is meant an antibody that can inhibit the activity (e.g., the ability to enter a target cell) of HIV isolates from more than one genetic subtype or clade.

[0048] By “CD4-inducible epitope on HIV Env that is distinct from the co-receptor binding site on gp120” is meant that an antibody of the invention does not compete with an HIV co-receptor (e.g., CCR5 or CXCR4) for the co-receptor binding site on gp120. One of ordinary skill in the art will understand how to determine whether an antibody competes with a co-receptor for the co-receptor binding site on Env, using well-known techniques for measuring competition between two molecules for binding to a particular site on a third molecule.

[0049] By “selected” is meant that an antibody or antibody fragment of the invention is chosen or isolated from a group or library of candidate antibodies or antibody fragments using a screening assay for choosing or isolating antibodies with a desired characteristic (e.g., the ability to bind a complex comprising HIV gp120, CD4, and a co-receptor for HIV; or the ability to specifically bind a CD4-inducible epitope on HIV Env that is enhanced by the binding of Env to a co-receptor for HIV, wherein the CD4-inducible epitope is distinct from the HIV co-receptor binding site on gp120), as would be understood by one of ordinary skill in the art.

[0050] By “CD4-inducible epitope” is meant an antigenic site on HIV Env, gp120, or gp41, wherein specific binding to the antigenic site by an antibody of the invention is increased or augmented by the binding of CD4 to HIV Env, gp120, or gp41. Preferably the increase is by at least about 2-fold or greater, e.g., at least about: 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, or more. For example, the binding of the anti-HIV antibody X5 (described herein) to gp120 is increased by about 5- to 10-fold when CD4 is present (i.e., when gp120 is bound to CD4, e.g., sCD4).

[0051] By “exposure of the epitope is enhanced” or “epitope that is enhanced” is meant that specific binding of an antibody of the invention to its cognate CD4-inducible epitope on HIV Env, gp120, or gp41 is further augmented by the binding of HIV Env, gp120, or gp41 to a co-receptor for HIV (such as the chemokine receptor CCR5 or CXCR4). Preferably the increase is by at least about 1.2-fold or greater, e.g., at least about 1.3-, 1.4-, 1.5-, 1.6-, 1.7-, 1.8-, 1.9-, or 2-fold, or greater.

[0052] By “soluble CD4” or “sCD4” or D1D2” is meant a CD4 molecule, or a fragment thereof, that is in aqueous solution and that can mimic the activity of native membrane-anchored CD4 by altering the conformation of HIV Env, as is understood by those of ordinary skill in the art. One example of a soluble CD4 is the two-domain soluble CD4 (sCD4 or D1D2) described, e.g., in Salzwedel et al. J. Virol. 74:326-333, 2000.

[0053] By “isolated polypeptide” is meant a polypeptide (or a fragment thereof) that has been separated from the components that naturally accompany it. Typically, the polypeptide is substantially pure when it is at least 60%, by weight, free from the proteins and naturally-occurring organic molecules with which it is naturally associated. Preferably, the polypeptide is at least 75%, more preferably at least 80% or 90%, and most preferably at least 95%, by weight, pure. A substantially pure polypeptide may be obtained, for example, by extraction from a natural source.
(e.g., a cell), by expression of a recombinant nucleic acid encoding the polypeptide, or by chemically synthesizing the polypeptide. Purity can be measured by any appropriate method, e.g., by column chromatography, polyacrylamide gel electrophoresis, or HPLC analysis.

[0054] A protein is substantially free of naturally associated components when it is separated from those contaminants which accompany it in its natural state. Thus, a protein which is chemically synthesized or produced in a cellular system different from the cell from which it naturally originates will be substantially free from its naturally associated components. Accordingly, substantially pure polypeptides not only includes those derived from eukaryotic organisms but also those synthesized in E. coli or other prokaryotes.

[0055] By "isolated nucleic acid" is meant a nucleic acid molecule that is free of the genes which, in the naturally-occurring genome of the organism from which the DNA of the invention is derived, flank the gene. The term therefore includes, for example, a recombinant DNA which is incorporated into a vector, into an autonomously replicating plasmid or virus; or into the genomic DNA of a prokaryote or eukaryote; or which exists as a separate molecule (e.g., a cDNA or a genomic or cDNA fragment produced by PCR or restriction endonuclease digestion, or an mRNA transcribed from a recombinant DNA template) independent of other sequences. It also includes a recombinant DNA which is part of a hybrid gene encoding additional polypeptide sequence.

[0056] By "expression vector" is meant a DNA construct that contains a promoter operably linked to a downstream gene or coding region (e.g., a cDNA or genomic DNA fragment, which encodes a polypeptide or polypeptide fragment). Introduction of the expression vector into the appropriate recipient cell (e.g., a prokaryotic or eukaryotic cell, e.g., a bacterium, yeast, insect cell, or mammalian cell, depending upon the promoter within the expression vector) allows the cell to express mRNA encoded by the expression vector, which is then translated into the encoded polypeptide or polypeptide fragment. Vectors for in vitro transcription/translation are also well-known in the art. An expression vector may be a genetically engineered plasmid, virus, or artificial chromosome derived from, for example, a bacteriophage, adenovirus, retrovirus, poxvirus, or herpesvirus.

[0057] By "effective amount" is meant the amount of an anti-HIV antibody of the invention that is useful for treating, partially or completely inhibiting, or preventing an HIV infection in a patient or subject or partially or completely inhibiting entry of HIV into a cell, as described herein. Effective dosages and schedules for administering the antibodies of the invention may be determined empirically, and making such determinations is routine to one of ordinary skill in the art. The skilled artisan will understand that the dosage of anti-HIV antibody will vary, depending upon, for example, the species of the subject the route of administration, the particular antibody to be used, other drugs being administered, and the age, condition, sex and extent of the disease in the subject. The dosage can be adjusted by the individual physician in the event of any counter-indications. A effective dose of an anti-HIV antibody of the invention generally will range between about 1 µg/kg of body weight and 100 mg/kg of body weight. Examples of such dosage ranges are (but are not limited to), e.g., about 1 µg-100 µg/kg 100 µg-1 mg/kg, 1 mg/kg-10 mg/kg, or 10 mg-100 mg/kg, once a week, bi-weekly, daily, or two to four times daily.

DESCRIPTION OF THE DRAWINGS

[0058] FIG. 1 is a bar graph showing that the X5 epitope is induced by sCD4 and its exposure enhanced by daCCR5. BSA, gp120IRES, gp120IRES+CD4, gp120µg, CD4, sCD4 (D112) or daCCR5 (100 ng each in 0.1 ml solution) were coated on an ELISA plate overnight at 4°C after which the wells were blocked with 4% milk in Tris-buffered saline. Detergent (0.5% Cymal-5)-solubilized CCR5 (daCCR5) at 100 ng per well containing 0.1 ml buffer was added. In control experiment without daCCR5 Cymal-5 (0.5%) buffer was added and incubated overnight at 4°C then X5 Fab was used as primary antibody (Ab) followed by goat anti-human F(ab')2-HRP to detect the signal.

[0059] FIG. 2 is a diagram showing binding isotherms of X5 to gp120 and gp120-sCD4. Experimental data for gp120IRES.6 and sCD4-gp120IRES.6 obtained as described for FIG. 1 were analyzed by fitting them to an equation describing the Langmuir adsorption isotherm (B/Bo = X5/Kd + X5), where B is the amount of bound X5, Bo is the maximal amount of bound X5, X5 is its bulk concentration and Kd is the equilibrium dissociation constant (affinity is the inverse of Kd). The continuous lines represent fitting of the data for X5 binding to gp120IRES.6 (lower curve) and sCD4-gp120IRES.6 (upper curve) with Kd equal to 9.3 mM and 1.0 mM, respectively.

[0060] FIG. 3 is a graph showing binding of antibodies X5, b12, and 17b to cell surface-associated functional oligomeric gp120-rgg41. The T-cell line H9 was infected with the HIV-1 TCLA X4 MN isolate for 10 days. At this time post-infection there was no detectable CD4 remaining at the cell surface, and no syncytium formation in the culture, but strong Env expression was detected using gp120-specific mAbs and flow cytometry. H9 cells were pre-incubated with sCD4 (20 µg/ml) or buffer alone for 1 h at RT, then incubated with X5 Fab, the anti-CD41 mAb 17b or the anti-CD41BS Fab IgG1b12 at various concentrations. The amount of bound antibodies was measured by flow cytometry.

[0061] FIG. 4 is a bar graph showing inhibition of sCD4-induced fusion by X5. Fusion between 293 cells, expressing CCR5 or CXCR4 after infection with recombinant vaccinia viruses (PM1107 or DM1107, respectively), and 293 cells, expressing HIV-1X4, Env after infection with recombinant vaccinia virus, induced by soluble CD4, was measured by the beta-galactosidase assay. The Env-expressing cells were mixed with sCD4 (1 µg/ml) and X5 (0, 125, 250, 500 ng/ml) for 30 min at 37°C. In a control experiment (con) no sCD4 was added. These cells were mixed with the cells expressing receptor molecules at a ratio of 1:1 (total number of cells equal to 2×105 in 96-well plate format). Fusion was allowed to proceed for 2 h at 37°C and quantitated by a colorimetric assay which measures the optical density at 595 nm (OD595).

[0062] FIGS. 5A and 5B are graphs showing neutralization of HIV infection by X5. Infection of HOS CD4.CXCR4 or HOS CD4.CCR5 cells by pseudotyped HIV-1NL4-3 was monitored by a reporter gene assay performed as described in the Materials and Methods section of Example 1.

[0063] FIGS. 6A and 6B are graphs showing antibody competition assays for characterization of the X5 epitope.
characterize the X5 epitope, known CD-inducible monoclonal antibodies (mAbs) were tested in an competition ELISA assay. Nunc-Immuno™ Maxisorp™ surface plates (Nalge Nunc International, Denmark) were coated with 100 ul of gp120 (FIG. 6A) or gp120+CD4 (FIG. 6B) (0.5 ug/ml each) in carbonated buffer, blocked with 4% milk in TBS. Fab X5 was biotinylated and a fixed concentration (0.5 ug/ml) was added to each well along with increasing concentrations (0, 0.01, 0.1, 1, 10 ug/ml) of indicated mAbs. Binding of biotinylated X5 was detected using streptavidin-HRP secondary Ab. Unbiotinylated X5 was also tested (at 0, 0.01, 0.1, 1, and 10 ug/ml) and more than 50% inhibition was detected at 1 ug/ml concentration.

[0064] FIG. 7 is a diagram showing the sequence of the X5 light chain (SEQ ID NO: 2). The OmpA signal sequence, three framework regions (FR1-FR3), three complementarity-determining regions (CDR1-CDR3), kappa chain joining region (JK), and light chain constant region (CL) are indicated by heavy horizontal lines above the relevant amino acids.

[0065] FIG. 8 is a diagram showing the sequence of the X5 heavy chain (SEQ ID NO: 3). The PeiB signal sequence, four framework regions (FR1-FR4), three complementarity-determining regions (CDR1-CDR3), and heavy chain constant regions 1 (CH1) are indicated by heavy horizontal lines above the relevant amino acids. The two amino acid positions that are substituted in the X5 sequence variant FabB (described in Example II), are shown below the original X5 heavy chain sequence.

DETAILED DESCRIPTION OF THE INVENTION

[0066] Binding of the HIV envelope glycoprotein (also known as Env or gp120-gp41) to CD4 and the co-receptor CCR5 or CXCR4 initiates a series of conformational changes that are the heart of the fusion machinery leading to viral entry. The elucidation of the nature of the Env conformational changes is not only a clue to the mechanism of HIV-1 entry but also provides new tools for the development of inhibitors and vaccines.

[0067] Described herein is a novel approach for the identification of broadly cross-reactive antibodies that neutralize multiple genetic subtypes of HIV. This approach involves the use of purified Env-CD4-co-receptor complexes for screening libraries of antibodies or antibody fragments that specifically bind to receptor-inducible HIV epitopes. Such antibodies can be used for treating, inhibiting, and/or preventing HIV infection by providing passive immunity to treated individuals. Currently there are known only three well-characterized monoclonal antibodies with broadly neutralizing activity, and none of these antibodies is directed against a receptor-inducible epitope.

[0068] Using this approach, a novel human antibody Fab fragment, denoted "X5", was identified by screening a phage display library, as described in Example I below. The epitope recognized by the X5 antibody is inducible by CD4 and exposure of the epitope is enhanced by the major HIV-1 co-receptor CCR5. The antibody neutralizes R5 and R5X4 viruses, including primary isolates, and to lesser extent, X4 viruses. Sequence variants and antibody fusion proteins based on X5 are also described herein, and will be apparent to those of ordinary skill in the art.

Antibodies

[0069] The term "antibodies" is used herein in a broad sense and includes both polyclonal and monoclonal antibodies. In addition to intact immunoglobulin molecules, also included in the term "antibodies" are fragments of immunoglobulin molecules and multimers of immunoglobulin molecules (e.g., diabodies, triabodies, and tri-specific and tri-specific antibodies, as are known in the art; see, e.g., Hudson and Kortt, J. Immunol. Methods 231:177-189, 1999), fusion proteins containing an antibody or antibody fragment (e.g., a fusion protein containing a fragment of CD4, e.g., scCD4 (Salzedo et al. J. Virol. 74:326-333, 2000), which are produced using standard molecular biology techniques, single chain antibodies, and human or humanized versions of immunoglobulin molecules or fragments thereof, as long as they are chosen for their ability to broadly neutralize HIV (e.g., multiple genetic subtypes of HIV-1 or HIV-2) by binding a CD4-inducible HIV epitope that is enhanced by binding an HIV co-receptor, as described herein. The antibodies are tested for their desired activity using the in vitro assays described herein, or by analogous methods, after which their in vivo therapeutic and/or prophylactic activities are tested according to known clinical testing methods.

[0070] The term "monoclonal antibody" as used herein refers to an antibody or antibody fragment obtained from a substantially homogeneous population of antibodies or antibody fragments, i.e., the individual antibodies within the population are identical except for possible naturally occurring mutations that may be present in a small subset of the antibody molecules. The monoclonal antibodies herein specifically include "chimeric" antibodies in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, as long as they exhibit the desired antagonistic activity (See U.S. Pat. No. 4,816,567 and Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984)).

[0071] Monoclonal antibodies of the invention can be prepared using hybridoma methods, as those described by Kohler and Milstein, Nature, 256:495 (1975). In a hybridoma method, a mouse or other appropriate host animal is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes may be immunized in vitro, e.g., using the HIV Env-CD4-co-receptor complexes described herein.

[0072] The monoclonal antibodies may also be made by recombinant DNA methods, as those described in U.S. Pat. No. 4,816,567 (Cabilly et al.). DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). Libraries of antibodies or active antibody fragments can also be generated and screened using phage display techniques, e.g., as described in U.S. Pat. No.
Human Antibodies


[0078] The human antibodies of the invention can also be obtained from transgenic animals. For example, transgenic, mutant mice that are capable of producing a full repertoire of human antibodies, in response to immunization, have been described (see, e.g., Jakobovits et al., Proc. Natl. Acad. Sci. USA, 90:2551-255 (1993); Jakobovits et al., Nature, 362:255-258 (1993); Druggerman et al., Year in Immunol., 7:33 (1993)). Specifically, the homologous deletion of the antibody heavy chain joining region (J(H)) gene in these chimeric and germ-line mutant mouse lines results in complete inhibition of endogenous antibody production, and the successful transfer of the human germ-line antibody gene array into such germ-line mutant mouse lines results in the production of human antibodies upon antigen challenge. Antibodies having the desired activity are selected using Env-CD4 coreceptor complexes as described herein.

Humanized Antibodies

[0080] Antibody humanization techniques generally involve the use of recombinant DNA technology to manipulate the DNA sequence encoding one or more polypeptide chains of an antibody molecule. Accordingly, a humanized form of a non-human antibody (or a fragment thereof) is a chimeric antibody or antibody chain (or a fragment thereof, such as an Fv, Fab, Fab′, or other antigen-binding portion of an antibody) which contains a portion of an antigen binding site from a non-human (donor) antibody integrated into the framework of a human (recipient) antibody.

[0081] To generate a humanized antibody, residues from one or more complementarily determining regions (CDRs) of a recipient (human) antibody molecule are replaced by residues from one or more CDRs of a donor (non-human) antibody molecule that is known to have desired antigen binding characteristics (e.g., a certain level of specificity and affinity for the target antigen). In some instances, Fv framework (FR) residues of the human antibody are replaced by corresponding non-human residues. Humanized antibodies may also contain residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies. Humanized antibodies generally contain at least a portion of an antibody constant region (Fc), typically that of a human antibody (Jones et al., Nature, 321:522-525 (1986), Reichmann et al., Nature, 332:323-327 (1988), and Presta, Curr. Opin. Struct. Biol., 2:593-596 (1992)).

Administration of Antibodies

Antibodies of the invention are preferably administered to a subject in a pharmaceutically acceptable carrier. Suitable carriers and their formulations are described in Remington: The Science and Practice of Pharmacy (19th ed.) ed. A. R. Gennaro, Mack Publishing Company, Easton, Pa. 1995. Typically, an appropriate amount of a pharmaceutically acceptable salt is used in the formulation to render the formulation isotonic. Examples of the pharmaceutically acceptable carrier include, but are not limited to, saline, Ringer's solution and dextrose solution. The pH of the solution is preferably from about 5 to about 8, and more preferably from about 7 to about 7.5. Further carriers include sustained release preparations such as semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g., films, liposomes or microparticles. It will be apparent to those persons skilled in the art that certain carriers may be more preferable depending upon, for instance, the route of administration and concentration of antibody being administered.

The antibodies can be administered to the subject, patient, or cell by injection (e.g., but not limited to, intravenous, intraperitoneal, intradermal, subcutaneous, intramuscular), or by other methods such as infusion that ensure its delivery to the bloodstream in an effective form. Local or intramuscular injection is preferred.

Effective doses and schedules for administering the antibodies may be determined empirically, and making such determinations is within the skill of the art. Those skilled in the art will understand that the dosage of antibodies that must be administered will vary depending on, for example, the subject that will receive the antibody, the route of administration, the particular type of antibody used and other drugs being administered. Guidance in selecting appropriate doses for antibodies is found in the literature on therapeutic uses of antibodies, e.g., Handbook of Monoclonal Antibodies, Ferrone et al., eds., Noges Publications, Park Ridge, N.J. (1985) ch. 22 and pp. 303-357; Smith et al., Antibodies in Human Diagnosis and Therapy, Haber et al., eds., Raven Press, New York (1977) pp. 365-389. A typical daily dosage of the antibody used alone might range from about 1 mg/kg to up to 100 mg/kg of body weight or more per day, depending on the factors mentioned above.

Following administration of an antibody for treating, inhibiting, or preventing an HIV infection, the efficacy of the therapeutic antibody can be assessed in various ways well known to the skilled practitioner. For instance, one of ordinary skill in the art will understand that an antibody of the invention is efficacious in treating or inhibiting an HIV infection in a subject by observing that the antibody reduces viral load or delays or prevents a further increase in viral load. Viral loads can be measured by methods that are known in the art, for example, using polymerase chain reaction assays to detect the presence of HIV nucleic acid or antibody assays to detect the presence of HIV protein in a sample (e.g., but not limited to, blood or another body fluid) from a subject or patient, or by measuring the level of circulating anti-HIV antibodies in the patient. Efficacy of the antibody treatment may also be determined by measuring the number of CD4+ T cells in the HIV-infected subject. An antibody treatment that delays or inhibits an initial or further decrease in CD4+ T cells in an HIV-positive subject or patient, or that results in an increase in the number of CD4+ T cells in the HIV-positive subject, is an efficacious antibody treatment.

The broadly-neutralizing antibodies of the invention can also be administered prophylactically to patients or subjects who are at risk for being exposed to HIV or who have been newly exposed to HIV. Such patients include, but are not limited to, healthcare workers; fetuses, neonates, or infants (e.g., nursing infants) whose mothers are infected or at risk for being infected; intravenous drug users; recipients of blood transfusions, blood products, or transplantation tissue; and other individuals who have been exposed to a body fluid that contains or may contain HIV.

In subjects who have been newly exposed to HIV but who have not yet displayed the presence of the virus (as measured by PCR or other assays for detecting the virus) in blood or other body fluid, efficacious treatment with an antibody of the invention partially or completely inhibits or delays the appearance of the virus or minimizes the level of the virus in the blood or other body fluid of the exposed individual.

Nucleic Acid Approaches for Antibody Delivery

The broadly neutralizing anti-HIV antibodies and antibody fragments of the invention can also be administered to patients or subjects as a nucleic acid preparation (e.g., DNA or RNA) that encodes the antibody or antibody fragment, such that the patient's or subject's own cells take up the nucleic acid and produce and secrete the encoded antibody or antibody fragment, thereby treating, inhibiting, or preventing HIV infection.

Nucleic Acid Delivery

In the methods described above which include the administration and uptake of exogenous DNA into the cells of a subject (i.e., gene transduction or transfection), the nucleic acids of the present invention can be in the form of free DNA or RNA, or the nucleic acids can be in a vector for delivering the nucleic acids to a cell and expressing the encoded polypeptide within a cell, whereby the antibody-encoding DNA fragment is under the transcriptional regulation of a promoter, as well as an other necessary and/or desirable components to regulate and/or enhance transcription and/or stability of the mRNA and to regulate and/or enhance translation of the encoded polypeptide, as would be well understood by one of ordinary skill in the art. The vector can be a commercially available preparation, such as a plasmid or an adeno virus vector (Quantum Biotechnologies, Inc. (Laval, Quebec, Canada)).
[0091] Delivery of the nucleic acid or vector to cells can be via a variety of mechanisms. As one example, delivery can be via a liposome, using commercially available liposome preparations such as LIPOFECTIN, LIPOFECTAMINE ( Gibco-BRL, Inc., Gaithersburg, Md.), SUPERFECT (Qiagen, Inc. Hilden, Germany), and TRANSPECTAM (Promega Biotech, Inc., Madison, Wis.), as well as other liposomes developed according to procedures standard in the art. Delivery can also be by injection (e.g., but not limited to, intravenous or intramuscular) of naked DNA, e.g., in a plasmid or viral vector. In addition, the nucleic acid or vector of this invention can be delivered in vivo by electroporation, the technology for which is available from Genetronics, Inc. (San Diego, Calif.) as well as by means of a SONOPORATION machine (ImaRx Pharmaceutical Corp., Tucson, Ariz.).

[0092] As one example, vector delivery can be via a viral system, such as a retroviral vector system which can package a recombinant retroviral genome (see e.g., Pastan et al., Proc. Natl. Acad. Sci. USA, 85:4486, 1988; Miller et al., Med. Cell. Biol. 6:2895, 1986). The recombinant retrovirus can then be used to infect and thereby deliver to the infected cells nucleic acid encoding a broadly neutralizing antibody (or active fragment thereof) of the invention. The exact method of introducing the altered nucleic acid into mammalian cells is, of course, not limited to the use of retroviral vectors. Other techniques are widely available for this procedure including the use of adenoviral vectors (Mittani et al., Hum. Gene Ther. 5:941-948, 1994), adenovirus-associated viral (AAV) vectors (Goodman et al., Blood 84:1492-1500, 1994), lentiviral vectors (Naldini et al., Science 272:263-267, 1996), or pseudotyped retroviral vectors (Agrawal et al., Exp. Hematol. 24:738-747, 1996). Physical transduction techniques can also be used, such as liposome delivery and receptor-mediated and other endocytosis mechanisms (see, for example, Schwartzengerber et al., Blood 87:472-478, 1996). This invention can be used in conjunction with any of these or other commonly used gene transfer methods.

[0093] For example, if the antibody-encoding nucleic acid of the invention is delivered to the cells of a subject in an adenovirus vector, the dosage for administration of adenovirus to humans can range from about 10^7 to 10^9 plaque forming units (pfu) per injection but can be as high as 10^12 pfu per injection (Crystal, Hum. Gene Ther. 8:985-1001, 1997; Alvarez and Curiel, Hum. Gene Ther. 8:597-613, 1997). A subject can receive a single injection, or, if additional injections are necessary, they can be repeated at six month intervals (or other appropriate time intervals, as determined by the skilled practitioner) for an indefinite period and/or until the efficacy of the treatment has been established.

[0094] Parenteral administration of the nucleic acid or vector of the present invention, if used, is generally characterized by injection. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution of suspension in liquid prior to injection, or as emulsions. A more recently revised approach for parenteral administration involves use of a slow release or sustained release system such that a constant dosage is maintained. See, e.g., U.S. Pat. No. 3,610,795, which is incorporated by reference herein. For additional discussion of suitable formulations and various routes of administration of therapeutic compounds, see, e.g., Remington: The Science and Practice of Pharmacy (19th ed.) ed. A. R. Gennaro, Mack Publishing Company, Easton, Pa. 1995.

[0095] The present invention is more particularly described in the following examples, which are intended as illustrative only, since numerous modifications and variations therein will be apparent to those of ordinary skill in the art.

EXAMPLE 1

Identification of X5, an Fab Fragment that has Broadly Neutralizing Activity Against HIV-1


[0097] Cells, viruses, plasmids, soluble CD4, gp120, gp140 and mAbs. ST3 cells expressing CD4 and CCR5 were gift from D. Littman (New York University, NY, N.Y.). C227 cells expressing high amounts of CCR5 were gift from J. Sodroski (Dana Farber Institute, Boston, Mass.). The parental cells was purchased from ATCC and used as negative control. The stable cell line TF228 expressing LAM Env was a gift from Z. Jonak (SmithKline Beecham Pharmaceuticals, Philadelphia, Pa.) through R. Blumenthal (NCI-Frederick, Frederick, Md.). Recombinant vaccinia viruses used for the reporter gene fusion assay were described previously (Nassbaum et al. J. Virol. 68:5411-5422, 1994). Plasmids expressing various Env's were obtained through the NIH AIDS Research and Reference Reagent Program or were gift from M. A. Martin (NIAID, Bethesda, Md.). Two-domain soluble CD4 (scCD4 or D1D2) (see e.g., Salzwedel et al. J. Virol. 74:326-333, 2000) was a gift from E. Berger (NIAID, Bethesda, Md.). Purified gp120aaa and gp140aaa were produced by recombinant vaccinia virus (gift of R. Doms, University of Pennsylvania, Philadelphia, Pa.) with a combination of lentil lectin affinity chromatography and size exclusion chromatography. Recombinant gp120aaa was a gift from A. Schultz and N. Miller (NIAID, Bethesda, Md.). The fusion protein gp120aaa-CD4 (Fouts et al. J. Virol. 74:11427-11436, 2000) was a gift from T. Fouts (Institute of Human Virology, Baltimore, Md.). The anti-CD4 polyclonal antibody T4-4 was obtained through the AIDS Research and Reference Reagent Program from R. Sweet (SmithKline Beecham Pharmaceuticals, Philadelphia, Pa.). The anti-gp120 mAbs 17b, 48d, 23e and 21e were gift from J. Robinson (Tulane University Medical Center, New Orleans, La.). The anti-CCR5 mAb 5C7 was a gift from L. Wu (Millenium Pharmaceuticals, Cambridge, Mass.). The goat polyclonal anti-CCR5 antibody CKR5(C20) was purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, Calif.).

[0098] Production, purification and quantification of gp120-CD4-CCR5 complexes. NIH 3T3 transfectants (10^6 in 100 ml) expressing high amounts of CD4 and CCR5 were washed twice with cold (4°C) phosphate-buffered saline (PBS) then pelleted by centrifugation and resuspended in 100 ml lysis buffer (1% Brij 97, 5 mM indoxacetamide, added immediately before use, 150 mM NaCl, 20 mM Tris (pH 8.2), 20 mM EDTA, and protease inhibitors) at 4°C for 40 min with gentle mixing. An anti-CCR5 antibody at 2 μg/ml was added to the cell suspension and incubated with gentle mixing for 4 hours at 4°C. The nuclei were pelleted by centrifugation at 14,000 rpm for 25 min in a refrigerated centrifuge. Protein G-Sepharose beads (Sigma, St. Louis,
Mo.) (1 ml) prewashed with PBS were added to the cell lysate and incubated at 4°C for 14 hours. The beads were then washed five times with 100 ml of ice cold lysis buffer and incubated with JRF1 gp120 at 5 µg/ml in 20 ml lysis buffer for 1 hour at 4°C. They were again washed five times with 100 ml cold lysis buffer, incubated with 1% formaldehyde overnight, washed twice with cold lysis buffer and used. They contained approximately 0.01 mg CD4 and 0.02 mg gp120, as quantified by labeling amounts of soluble CD4 and gp120. For quantification of CD4 and gp120 two duplicated samples each containing 0.1% of the total amount of bead-associated gp120-CD4-CCR5 complexes were used. They were eluted by adding 4x sample buffer for SDS-PAGE gel and kept overnight at 37°C. They were run on a 10% SDS-PAGE gel simultaneously with calculating amounts (1, 3, 10, 30, 100 ng) of soluble four-domain CD4 (scCD4) (see e.g., Deen et al, *Nature* 331:82-84, 1988) or gp120 and were electrophoretically transferred to nitrocellulose membranes. The membranes were blocked with 20 mM tris-HCl (pH 7.6) buffer containing 140 mM NaCl, 0.1% Tween-20 and 5% nonfat powdered milk. For Western blotting these membranes were incubated with anti-CD4 or anti-gp120 antibodies, then washed and incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies. They were developed by using the supersignal chemiluminescent substrate from Pierce (Rockford, Ill.). The images were acquired by a BioRad phosphorimager (BioRad, Hercules, Calif.). The signal from the calibrating molecules was integrated for each band and plotted in a calibration curve for the signal vs. amount dependence. The amounts of CD4 and gp120 were then calculated by interpolation using the calibration curve.


**Production and purification of detergent solubilized CCR5** (dCCR5). dCCR5 was produced by a methodology adapted from that described previously (Mirzabeik et al. *J. Biol. Chem.* 274:28745-28750, 1999).

**Cell-cell fusion inhibition assay.** The gene reporter cell-cell fusion assay was previously described (Russbaum et al. *J. Virol.* 68:5411-5422, 1994). Briefly, recombinant vaccinia viruses at multiplicity of infection 10 were used to infect the target (vCB218) and effector cells (v7D7.3 plus virus expressing the HIV-1 Env). The p-gal fusion assay was performed two hours after mixing the cells. The extent of fusion was quantitated calorimetrically. Fusion induced by scCD4 was performed by incubation of 10⁵ effector cells expressing the Env with scCD4 (1 µg/ml) at 37°C for 30 min before mixing with the target cells (Salzwedel et al. *J. Virol.* 74:326-333, 2000). The inhibitory effect of X5 was evaluated by mixing the effector cells with X5 for 30 min at 37°C and then performing the fusion assay.

**HIV neutralization assay.** Virus neutralization assays were performed by using infection with a luciferase reporter HIV-1 Env pseudotyping system (Connor et al. *Virology* 206:935-944, 1995). Viral stocks were prepared by transfecting 293T cells with plasmids encoding the luciferase virus backbone (pNL-U6- Luc-ER) and Env from various HIV strains. The resulting supernatant was clarified by centrifugation for 10 min at 2,000 rpm in a Sorvall RT-7 centrifuge (RTH-750 rotor), passed through a 45-um pore size sterile filter (Millipore, Bedford, Mass.) and used or stored at –80°C. The virus was pre-incubated with various concentrations of X5 (0.1, 1.0, 10.0, 50, and 80 or 100 µg/ml) for 30 min at 37°C. Cells were then infected with 50 µl of virus preparation for 4 h at 37°C, then fresh media was added and incubation was continued for 48 h. Cells were then washed with PBS and lysed with luciferase assay buffer (Promega, Madison, Wis.). Luciferase activity was determined by adding 50 µl of freshly prepared luciferase assay substrate to 50 µl of cell lysate and measuring the intensity of chemiluminescence in a Lumicount microplate luminometer (Turner Designs, Sunnyvale, Calif.). All experiments were performed at least in triplicate and the results expressed as relative light units (RLU) per second.
non-fat milk (Biorad) in order to prevent nonspecific binding. The plates were washed with PBS containing 0.1% Tween-20, dscCCR5 in Cymal lysis buffer (1% Cymal, 100 mM (NH₄)₂SO₄, 20 mM Tris, 10% glycerol) was then added and incubated at 4°C overnight. Unbound molecules of dscCCR5 were washed and X5 was added. After washing bound X5 was detected by anti-human IgG.

[0108] The antibody competition experiment was performed by using a mixture of the competing Ab (at different concentrations) with 0.5 μg/ml biotinylated X5 instead of X5 alone following the procedure as described above. Biotinylated proteins were prepared by incubation with 2 nM biotin (prepared from solid NHS-lys-Biotin (Pierce, Calif.) dissolved at 200 μM in DMSO as stock solution) on wet ice for 1 h. The biotinylation was quenched with 20 μM glycine on ice for 15 min. Binding of biotinylated X5 was detected using streptavidin-HRP secondary antibody.

[0109] Flow cytometry. Cells (typically 0.5×10⁶) were incubated for 1 h on ice with the antigen specific antibodies. They were washed, and incubated for another hour on ice with rabbit IgG (10 μg/ml) (Sigma, St. Louis, Mo.) to improve the specificity, then washed and incubated for 1 h with an anti-mouse phycoerythrin-conjugated polyclonal antibody (Sigma). The cells were washed and fixed with paraformaldehyde on ice for 10 min. The flow cytometry measurements were performed with FACSCalibur (Becton Dickinson, San Jose, Calif.).

[0110] Binding of Env-specific antibodies to HIV-1-infected cells. The I-cell line H9 (a gift from Q. Sattentau and supplied by the MRC AIDS Reagent Project) was grown in RPMI1640 supplemented with 10% fetal calf serum. H9 cells were infected with the HIV-1 TCLA X4 MN isolate (obtained through the AIDS Research and Reference Reagent Program from R. Gallo) for 10 days to achieve high level of Env expression as detected by gp120-specific mAbs and flow cytometry (see above). Then the antibodies were added at various concentrations, the cells were washed twice, and the bound human antibodies detected using anti-human IgG by flow cytometry as described above.

[0111] B) Results.

[0112] Selection of a phage (X5) with high affinity to gp120-CD4-CCR5 complexes. For phages we used complexes containing about 0.01 mg CD4 and 0.02 mg JRFL gp120. The amount of CCR5 was not determined precisely but was about 0.01 mg as found by comparison of CCR5 Western blots of known amounts of detergent-solubilized CCR5. After 5 rounds of panning one phage was selected. This phage, denoted X5, was amplified. X5 exhibited binding activity to protein G cross-linked to Sepharose beads with an affinity (equilibrium dissociation constant) of 15 nM. Phase-displayed X5 had 15-fold lower effective affinity (1.4 nM) for protein G beads than for the gp120-CD4-CCR5 complex (0.09 nm). The X5 Fab was purified by using protein G columns.

[0113] Binding of X5 to a CD4-inducible epitope on gp120 that is enhanced by dsCCR5. To find whether the Fab of the selected phage was able to bind gp120 and its complexes with CD4 and CCR5 we used an ELISA-type of assay. X5 bound gp120 from several isolates and its binding was increased 5-10-fold after binding of scCD4 (D1D2) to gp120 (FIGS. 1 and 2). The affinity of binding (equilibrium dissociation constants) to gp120₉₀₀₀₉₀₀₀₉₀₀₀ and scCD4-gp120₉₀₀₉₀₀₉₀₀ complexes was 9.4 nM and 1 nM (FIG. 2), and for JRFL-10 and 2 nM, respectively (FIG. 1). Binding of dsCCR5 further enhanced the X5 epitope exposure by 30-60% (FIG. 1). Similar affinities were observed for binding to oligomeric, fusion-active gp120-gp41 showed expressed at the surface of chronically infected H9 cells (FIG. 3). For this experimental system the X5 affinity in presence of scCD4 was comparable to that of CD4bs-specific mAb IgG1b12 in the absence of scCD4 and several fold higher than the affinity of 17b which was previously reported to exhibit an increased affinity to the gp120-CD4 complex (Thali et al., J. Virol., 67:3978-3985 1993). The affinity of X5 for the gp120₁₂₅₁₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅₋₅_-...
with X5 in the ELISA assay. Very low competition was observed with 17b at high concentrations (FIGS. 6A and 6B), suggesting slight epitope overlap or steric interference. Although we were not able to localize precisely the X5 epitope it appears that it is close to the gp41 association site with gp120, as indicated by the poorer binding of all gp140 EnvS compared to gp120s. Studies of X5 competition with more antibodies with known epitopes and the X5 crystal structure in combination with the known gp120 core structure will facilitate determination of the precise epitope recognized by X5. The amino acid sequences of the X5 light and heavy chains are shown in FIGS. 7 and 8, respectively.

EXAMPLE II

Generation of X5 Antibody Sequence Variants with Increased Affinity for Env-CD4-Co-Receptor Complexes

[0117] The amino acid sequence of any antibody or antibody fragment of the invention may be varied in order to generate variant antibodies with equivalent or improved affinity for Env-CD4-co-receptor complexes. Such variant antibodies can be created and tested for their relative affinity using well-known methods and/or methods described herein. Such techniques are described, e.g., in Daugherty et al. ("Quantitative analysis of the effect of the mutation frequency on the affinity maturation of single chain Fv antibodies." Proc. Natl. Acad. Sci. USA 97(5):2029-34, 2000); Cherry et al. ("Directed evolution of a fungal peroxidase." Nat. Biotechnol. 17(4):379-84, 1999); and Vartanian et al. ("Hypermutagenic PCR involving all four transitions and a sizeable proportion of transversions." Nucleic Acids Res. 24(14):2627-31, 1996).

[0118] Random mutagenesis of the X5 antibody gene was used to identify X5 sequence variants with improved affinity for Env-CD4-CCR5 and Env-CD4 complexes. Two-phase X5 mutagenesis libraries, one expressing antibody X5 sequence variants as Fab fragments and the other expressing antibody X5 as scFv (single chain antibody) fragments, were constructed and panned sequentially against both complexes using methods similar to those described in Example I above. One Fab clone was selected from the X5-Fab mutagenesis library. The new X5-Fab clone, designated FabS, showed five-fold increased affinity for Env-CD4-CCR5 complex, compared to the original X5-Fab. The mutations were located in the joint region between the heavy chain variable region and the first constant domain (CH1), in which the alanine in the original X5 sequence was changed to proline and the serine in the original sequence was changed to glycine (SEQ ID NO: 11; FabS heavy chain sequence), as shown in FIG. 4. The nucleic sequence encoding the light and heavy chains of FabS is set forth in SEQ ID NO: 12.

EXAMPLE III

Generation of Antibody Fusion Polypeptides Based on the X5 Antibody Sequence

[0119] Fusion proteins comprising antibody fragments and other functional domains which increase the efficacy of the antibody in treating, inhibiting, or preventing HIV infection are contemplated to be made using standard techniques that are well known in the art, and used in the methods of the invention for the treatment of and prophylaxis against infection by HIV. Below are several examples of fusion proteins based upon the X5 antibody fragment described, in Example I above. Two basic types of fusion proteins are shown: those based upon single-chain antibody (ScFv) fragments, and those based upon Fab fragments. One of ordinary skill in the art will understand that any antibody or antibody fragment of the invention can be used to generate these and other types of fusion proteins.

[0120] The first example of such a fusion protein is a SeFvX5-CD4 fusion protein, i.e., a single-chain antibody (ScFv) fragment comprising a domain from the variable region of the X5 heavy chain (VH) and a domain from the variable region of the X5 light chain (VL), fused to fused to soluble CD4 (sCD4). The VH and VL domains are separated by a fifteen amino acid long flexible linker consisting of three repeats of the pentapeptide Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 21), and the VL and sCD4 domains of the fusion protein are separated by a variable length flexible linker (e.g., containing 20, 30, or 40 amino acid residues) containing, e.g., four, six, or eight repeats of Gly-Gly-Gly-Gly-Ser. The components of this fusion protein, labeled a through e, are as follows. Although the example below shows the VH domain as being positioned amino-terminal to the VL domain (VH-Linker (L3)-VL-), one of ordinary skill in the art will readily recognize that the relative positions of the VH and VL domains can be swapped (e.g., VL-Linker (L3)-VH-) for all of the exemplary fusion protein constructs shown below.

A) SeFvX5-CD4 Fusion Protein

[0121] Construct: VH-Linker (L3)-VL-Linker (Variable Length)-sCD4 (a-b-c-d-e)

a) Variable Heavy Chain (VH) (SEQ ID NO: 14)

b) Linker (L) (Gly, Ser) x 3 (SEQ ID NO: 21)

c) Variable light chain (VL) (SEQ ID NO: 15)

d) Linker (Variable length-20 or 30 or 40 a.a. long) (Gly, Ser) x 4 or 6 or 8 (SEQ ID NO: 19)

e) sCD4 (two domain soluble CD4) (SEQ ID NO: 16, 17, or 18)

PEDLAYVYQQGTEFSYPSQYQQEELKET

MNGQYPPRSSLQILQGALLFAATQVHRY24KQSYTVLVSLDDECX19
C) Fab'-CD4 Fusion Protein

**[0126]** Construct: **VL.CL-ss-VHCH1-Linker (Variable Length)-sCD4**

- a) X5 Fab sequence
  - (SEQ ID NO: 3 plus 2 or SEQ ID NOs: 14 plus 15).
  - X5 Fab sequence (SEQ ID NO: 16, 17, or 18)
- b) Linker (Variable length-20 or 30 or 40 a.a long)
  - (Gly,Ser) × 4 or 6 or 8
  - (SEQ ID NO: 19)
- c) sCD4 (two domain)
  - CTAQKESLGPEEKNHKYQKLEQKLKGQGVLKPSIQLSKMDLGSQKEVEL
  - (SEQ ID NO: 20)
  - LVPGRATVSDTQQLGGEDLQGKMLQKLEQKLLEQKL

B) ScFv-CD4-T20 Fusion Protein

**[0123]** This construct is identical to construct A above, but in addition, after sCD4, contains another linker and the T-20 peptide:

- Linker (Gly,Ser) × 1
- T-20 peptide
- YTLHELHIGERQQKEKNEKQELLEDKWNMLSWEN

**[0124]** Below is an example of a fusion polypeptide containing an X5 Fab fragment, i.e., the X5 light chain fragment (VL.CL) containing the variable region and the constant region, which is disulfide-bonded (represented below by “-s-a”) to the heavy chain fragment containing the variable region and the CH1 portion of the constant region (VHCH1). One of skill in the art will recognize that X5 Fabs can contain heavy and light chains containing PelD, OmpA, or other signal sequences that direct protein secretion, e.g., as set forth in SEQ ID NOs: 5 and 2, respectively, or can contain heavy and light chains that lack such signal sequences, e.g., as set forth in SEQ ID NOs: 14 and 15, respectively.

**[0125]** The X5 Fab fusion protein shown below contains a soluble CD4 domain fused to the carboxy terminus of the X5 heavy chain. Constructs containing the sCD4 domain fused to the X5 light chain instead of the heavy chain may also be used.

**[0127]** The fourth construct is the same as the X5 Fab construct above, except it also contains a T20 domain. The T20 domain, like the sCD4 domain, may also be fused to either the heavy chain or the light chain. The construct below shows the T20 domain directly connected to the sCD4 domain by a flexible linker; however, constructs with the sCD4 domain on one chain and the T20 domain on the other chain (connected to the remainder of the chain by a flexible linker) are also included in the present invention.

D) Fab'-CD4-T20 Fusion Protein

**[0128]** Construct: **VL.CL-ss-VHCH1-Linker (Variable Length)-sCD4-L1-T20**

This construct is the same as construct C above, but, in addition, after sCD4 contains:

- Linker (Gly,Ser) × 1
- T-20 peptide
- YTLHELHIGERQQKEKNEKQELLEDKWNMLSWEN

**[0129]**

Amino Acid Sequence of X5 Light Chain including OmpA signal

- MKTAAAAMALDAPVAYQGXLVIQGQSPQSLSGFERTGSLCAGWQVGGASLAMTYQ
- KFQGSHLILVLGASTRGST0DFVSASGSDTPFLIGKLEDALWYQQVYWQPVTPPG
- QURLIEKRTVAPSFYIFPSDQILEGTAASVYCLNNTPVREAQVQKNVDALGQSGNSQ
- EVTHSDSRYLDSSTLSLKLQADYVHEKTVACEVHQILSSSTPFSFNGEC

**[0129]**

(SEQ ID NO: 2)
-continued

Amino Acid Sequence of X5 Heavy Chain, including PelB Signal.

MAVPLIVAGKLLAASAPQAEMAVLLEQLGGAYKPPSSYVSCCAGTGGTFLYFHV
QAPQHSLWNGEIIIPFPTSVYAKFPRGYVTMDAOQSTHAEMLTNASDDTAVTYCAR
PGFMDWEGDSYDSGGRFGDFWQQCTLYTVSSASTKSPVPLAPEKSTSGCTAAECGLV
KDTYFPVTVSMNGALTSGVHTPAVLSGSLSSVVTTFSSSSLGQTICYNVNHKFS
NTEYKAVFWPKSCCDTS

Nucleotide Sequence of X5
Length: 1539

1 atgaaaaaga caagcatctgg gattgaagtq gcctgacgctt gttcaaac
51 cgtgacccag ggcggcgagc tcggctctag cagctcaaca gcgaccgtg
101 ccggctgctg ggggaaga gccaacccct cctcgacggg cagtcagag
151 gttgacccag ggttcctgct gcctccacag cgaaccctgg gctggctgc
201 cagccctcct aatccagttg caatccattc ggcacctgcc acctccaga
251 gttacattgg gggagagctc tcaacccct acacgtacg
301 ctcagcgtct ggcagctagc aagttcgacg tggatcgctt tggatcgctt
351 cagcccctct tttgaccag gcaccaacca cgctggctgt gacagctgt
401 cggccctgtc ttcctggcgt ctcgactgct cgggagtgtc gttatcgat
451 gggaccagct ctgttgctat ccttcattc caagccagcc
501 ccacggccgg ctagaggtgt atacggcctt ccacggctt ggacgctacg
551 agacgctgct cggcagagc acgcgggacac gacacccacg ctcgaccg
601 acgcgctgca tgggacacag acaatcagag aaaaaaagac gcacgcgtgg
651 cggccctggt cggcgcgtc ccgctgctg ggcacataaa gggcccaaca
701 ttcctgtcct ttcctggtgc cttcagaggg tacatcctc ttcctacacc
751 ggtgagggat ttaatttct ctaattatc ecagaggtt caccatatag
801 tccctgcttc ttcctgcttc ttcctgcttc ttcctgcttc agcagctggt
851 cgtgcaccgt ctggcagcgg gggtcctcag tgcaccagctgt cttccctc
901 cgtgcaccg ctggcagcgg gcacaccgcag ttttagccag tgggcggcg
951 tgggcgaggg gggatccctt cttcattcct cttcattcct cttcattcct
1001 ggtgcaccag ctcgacggtt gccttcaccct gcttcaccct cttcattcct
1051 cttcattcct cttcattcct cttcattcct cttcattcct cttcattcct
1101 tgcaccagct cttcattcct cttcattcct cttcattcct cttcattcct
1151 tgggcggcg gggatccctt cttcattcct cttcattcct cttcattcct
1201 cttcattcct cttcattcct cttcattcct cttcattcct cttcattcct
1251 cttcattcct cttcattcct cttcattcct cttcattcct cttcattcct
1301 gttgcaccag ctcgacggtt gccttcaccct gcttcaccct cttcattcct
1351 ggtgcaccag ctcgacggtt gccttcaccct gcttcaccct cttcattcct
1401 cttcattcct cttcattcct cttcattcct cttcattcct cttcattcct
1451 tgggcggcg gggatccctt cttcattcct cttcattcct cttcattcct
1501 cttcattcct cttcattcct cttcattcct cttcattcct cttcattcct
Amino Acid Sequence of CDR3 Region of X5 Heavy Chain
DGQPDWEDUGSTDGSRGPPPDPY

Amino Acid Sequence of CDR2 Region of X5 Heavy Chain
GIPFQGESNYAQFRG

Amino Acid Sequence of CDR1 Region of X5 Heavy Chain
MYCEN

Amino Acid Sequence of CDR3 Region of X5 Light Chain
QQGQTSTYYTQLYFLSKE

Amino Acid Sequence of CDR2 Region of X5 Light Chain
GASTRAVTI

Amino Acid Sequence of CDR1 Region of X5 Light Chain
RAQQKYSQSGLAM

Amino Acid Sequence of Fab X5 Heavy Chain, including PelB Signal
MYLISDFTAAGGLLLIAAQFGAMSSLVQILLEQSSGAEXEVXKGSGYVSVCEKASOGTPFMSLYGGRKVRQ

Amino Acid Sequence of Fab X5 Light Chain
SWEDSSYDGSRGGFDPWQQMLVTVGSAGTSOGRPSVYFPLAPSSKETSOGTAALGCVKQY

Nucleotide Sequence of Fab X5
1 atgaaasasa caagctctagc gattgcaagt gcaatgctgt ggtcagtac
31 cgtgacccag gaggacagc tcgtgctgac acagctcctca gcaccctgtc
61 caagctctac acaagaggagc ctgcagcggt gcacccagtc ttcgacggt
91 cggcatcag cttttctatgc gagaagaac acaagctttg ctcctatcag
121 cttttctattc gtggagtttg gatttcagtt gcagcttcct
151 ctgcagcttc ttcttctattg ctcctatcag ctcctatcag ctcctatcag
181 ctcctatcag ctcctatcag ctcctatcag ctcctatcag ctcctatcag
211 ctcctatcag ctcctatcag ctcctatcag ctcctatcag ctcctatcag
241 ctcctatcag ctcctatcag ctcctatcag ctcctatcag ctcctatcag
271 ctcctatcag ctcctatcag ctcctatcag ctcctatcag ctcctatcag
301 ctcctatcag ctcctatcag ctcctatcag ctcctatcag ctcctatcag
331 ctcctatcag ctcctatcag ctcctatcag ctcctatcag ctcctatcag
361 ctcctatcag ctcctatcag ctcctatcag ctcctatcag ctcctatcag
391 ctcctatcag ctcctatcag ctcctatcag ctcctatcag ctcctatcag
421 ctcctatcag ctcctatcag ctcctatcag ctcctatcag ctcctatcag
451 ctcctatcag ctcctatcag ctcctatcag ctcctatcag ctcctatcag
481 ctcctatcag ctcctatcag ctcctatcag ctcctatcag ctcctatcag
511 ctcctatcag ctcctatcag ctcctatcag ctcctatcag ctcctatcag
541 ctcctatcag ctcctatcag ctcctatcag ctcctatcag ctcctatcag
571 ctcctatcag ctcctatcag ctcctatcag ctcctatcag ctcctatcag
601 ctcctatcag ctcctatcag ctcctatcag ctcctatcag ctcctatcag
631 ctcctatcag ctcctatcag ctcctatcag ctcctatcag ctcctatcag
661 ctcctatcag ctcctatcag ctcctatcag ctcctatcag ctcctatcag
691 ctcctatcag ctcctatcag ctcctatcag ctcctatcag ctcctatcag
721 ctcctatcag ctcctatcag ctcctatcag ctcctatcag ctcctatcag
751 ctcctatcag ctcctatcag ctcctatcag ctcctatcag ctcctatcag
781 ctcctatcag ctcctatcag ctcctatcag ctcctatcag ctcctatcag
811 ctcctatcag ctcctatcag ctcctatcag ctcctatcag ctcctatcag
841 ctcctatcag ctcctatcag ctcctatcag ctcctatcag ctcctatcag
871 ctcctatcag ctcctatcag ctcctatcag ctcctatcag ctcctatcag
901 ctcctatcag ctcctatcag ctcctatcag ctcctatcag ctcctatcag
931 ctcctatcag ctcctatcag ctcctatcag ctcctatcag ctcctatcag
961 ctcctatcag ctcctatcag ctcctatcag ctcctatcag ctcctatcag

INCORPORATION BY REFERENCE

[0130] All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each independent publication or patent application was specifically and individually indicated to be incorporated by reference.

OTHER EMBODIMENTS

[0131] While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure come within known or customary practice within the art to which the invention pertains and may be applied to the essential features hereinbefore set forth, and follows in the scope of the appended claims.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 21
<210> SEQ ID NO 1
<211> LENGTH: 10
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 1

gaagtagcgcc ttgacccg  
  10

<210> SEQ ID NO 2
<211> LENGTH: 217
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 2

Met Lys Lys Thr Ala Ile Ala Ile Ala Val Ala Leu Ala Gly Phe Ala  
  1   5   10   15

Thr Val Ala Gin Ala Ala Leu Val Leu Thr Gin Ser Pro Gly Thr  
  20  25  30

Leu Ser Leu Ser Ala Gly Gin Arg Ala Thr Leu Ser Cys Arg Ala Ser  
  35  40  45
| Gln Ser Val Ser Ser Gly Ser Leu Ala Trp Tyr Gln Gln Lys Pro Gly | 50  | 55  | 60 |
| Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly | 65  | 70  | 75 | 80 |
| Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu | 85  | 90  | 95 |
| Thr Ile Gly Arg Leu Glu Pro Glu Asp Leu Ala Val Tyr Tyr Cys Gln | 100 | 105 | 110 |
| Gln Tyr Gly Thr Ser Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu | 115 | 120 | 125 |
| Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser | 130 | 135 | 140 |
| Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn | 145 | 150 | 155 | 160 |
| Asn Phe Tyr Pro Arg Gly Ala Lys Val Gln Trp Lys Val Asp Asn Ala | 165 | 170 | 175 |
| Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu His Asp Ser Arg | 180 | 185 | 190 |
| Asp Ser Thr Tyr Ser Leu Gly Ser Thr Leu Thr Ser Lys Ala Asp     | 195 | 200 | 205 |
| Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu | 210 | 215 | 220 |
| Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys             | 225 | 230 | 235 |

**SEQ ID NO:** 3
**LENGTH:** 261
**TYPE:** PWT
**ORGANISM:** Artificial Sequence
**FEATURE:**
**OTHER INFORMATION:** Synthetic

```
| Met Lys Tyr Leu Leu Pro Thr Ala Ala Gly Leu Leu Leu Leu Ala | 1   | 5   | 10  | 15 |
| Ala Gln Pro Ala Met Ala Glu Val Gln Leu Glu Gln Ser Gly Ala | 20  | 25  | 30  |
| Glu Val Lys Lys Pro Gly Ser Ser Val Gln Val Ser Cys Gly Ala  | 35  | 40  | 45  |
| Gly Gly Thr Phe Ser Met Tyr Gly Phe Asn Trp Val Arg Gln Ala Pro | 50  | 55  | 60  |
| Gly His Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr | 65  | 70  | 75  | 80 |
| Ser Asn Tyr Ala Gln Lys Phe Arg Gly Arg Val Thr Phe Thr Ala Asp | 85  | 90  | 95  |
| Gln Ala Thr Ser Thr Ala Tyr Met Gln Leu Thr Asn Leu Arg Ser Asp | 100 | 105 | 110 |
| Asp Thr Ala Val Tyr Cys Ala Arg Asp Phe Gly Pro Asp Trp Glu    | 115 | 120 | 125 |
| Asp Gly Asp Ser Tyr Asp Gly Ser Gly Arg Gly Phe Phe Asp Phe Trp | 130 | 135 | 140 |
| Gly Gin Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro | 145 | 150 | 155 | 160 |
```
<table>
<thead>
<tr>
<th>165</th>
<th>Ser</th>
<th>Val</th>
<th>Phe</th>
<th>Pro</th>
<th>Leu</th>
<th>Ala</th>
<th>Pro</th>
<th>Ser</th>
<th>Ser</th>
<th>Lys</th>
<th>Ser</th>
<th>Thr</th>
<th>Ser</th>
<th>Gly</th>
<th>Gly</th>
<th>Thr</th>
</tr>
</thead>
<tbody>
<tr>
<td>170</td>
<td>Ala</td>
<td>Ala</td>
<td>Leu</td>
<td>Gly</td>
<td>Cys</td>
<td>Leu</td>
<td>Val</td>
<td>Lys</td>
<td>Asp</td>
<td>Tyr</td>
<td>Phe</td>
<td>Pro</td>
<td>Glu</td>
<td>Pro</td>
<td>Val</td>
<td>Thr</td>
</tr>
<tr>
<td>175</td>
<td>Val</td>
<td>Ser</td>
<td>Thr</td>
<td>Pro</td>
<td>Ser</td>
<td>Ser</td>
<td>Gly</td>
<td>Leu</td>
<td>Thr</td>
<td>Ser</td>
<td>Gly</td>
<td>Val</td>
<td>His</td>
<td>Thr</td>
<td>Phe</td>
<td>Pro</td>
</tr>
<tr>
<td>180</td>
<td>Ala</td>
<td>Val</td>
<td>Leu</td>
<td>Gin</td>
<td>Ser</td>
<td>Ser</td>
<td>Gly</td>
<td>Leu</td>
<td>Tyr</td>
<td>Ser</td>
<td>Leu</td>
<td>Ser</td>
<td>Ser</td>
<td>Val</td>
<td>Val</td>
<td>Thr</td>
</tr>
<tr>
<td>185</td>
<td>Val</td>
<td>Pro</td>
<td>Ser</td>
<td>Ser</td>
<td>Leu</td>
<td>Gly</td>
<td>Leu</td>
<td>Val</td>
<td>Thr</td>
<td>Gin</td>
<td>Thr</td>
<td>Tyr</td>
<td>Ile</td>
<td>Cys</td>
<td>Asn</td>
<td>Val</td>
</tr>
<tr>
<td>190</td>
<td>His</td>
<td>Lys</td>
<td>Pro</td>
<td>Ser</td>
<td>Ser</td>
<td>Thr</td>
<td>Lys</td>
<td>Val</td>
<td>Asp</td>
<td>Leu</td>
<td>Lys</td>
<td>Val</td>
<td>Pro</td>
<td>Lys</td>
<td>Ser</td>
<td>Thr</td>
</tr>
<tr>
<td>195</td>
<td>Cys</td>
<td>Asp</td>
<td>Lys</td>
<td>Thr</td>
<td>Ser</td>
<td>260</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<210> SEQ ID NO 4
<211> LENGTH: 1539
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE: Synthetic

<400> SEQUENCE: 4

```
attgaaasga caagcatagc gatgcaagtg gcacgctgtg cttgctgtac ctgqgccoaq  60
ggqgqgqag ctcggtgtgac acagcttacc ggacacccgt tgttgctgtc agqggqaaga 120
gcqccctct cttcgccggg caagcagagc ggtgagcgcg gcaccttacc cgtqtaacag 180
cqagaaccg cctgygtgtc acaaccacc gcacccctg cgcacccgtc 240
atcaccagc gttgactggt gcacggggtct ggqgqacta tacccttaa gccgqaga 300
cqgqagctg cagactaccc aqgtqtaatc tgtqgacag aqgtqtaacc 360
tttqgggacq gqgqaaccgc qgapqaga ggcqgtgcct tcqgtqtaacttc 420
ttcqgacq cgtqtaactgc qtaaqacqct tgtqgactq cttqgtqta 480
aqgctqta ccaacgqgq ccqaqccac gcqgqagcg acaaqacqtc gqgtqtaacc 540
caqacccgc agaqgqacqtc agaqgqacqtc agaqgqacqtc gqgtqtaacttc 600
aqccqacqtc qgqqaaccgc qgqqaaccgc qgqqaaccgc qgqqaaccgc 660
cqgqacqtc qgqqaaccgc qgqqaaccgc qgqqaaccgc qgqqaaccgc 720
atqaataqctt qagqgqatc tcqqaqacqtc qacqtcqccac qgtqgactq 780
qagqgqatc tcqqaqacqtc qagqgqatc tcqqaqacqtc qgtqgactq 840
qgqgqgqag cagqgqgqag cagqgqgqag cagqgqgqag cagqgqgqag 900
aqgqgqgqag cagqgqgqag cagqgqgqag cagqgqgqag cagqgqgqag 960
gqgqgqgqag cagqgqgqag cagqgqgqag cagqgqgqag cagqgqgqag 1020
tqqaqacqtc qaqacqtcqtcq tcqqaqacqtc qaqacqtcqtcq 1080
gqgqgqgqag cagqgqgqag cagqgqgqag cagqgqgqag cagqgqgqag 1140
tqqaqacqtc qaqacqtcqtcq tcqqaqacqtc qaqacqtcqtcq 1200
tqqaqacqtc qaqacqtcqtcq tcqqaqacqtc qaqacqtcqtcq 1260
tqqaqacqtc qaqacqtcqtcq tcqqaqacqtc qaqacqtcqtcq 1320
tqqaqacqtc qaqacqtcqtcq tcqqaqacqtc qaqacqtcqtcq 1380
```
-continued

tcatacactgcattatggtcatcgggtggtgcattataacacc 1440
caggtgaattcatagcgcaaaattcattatgtggcagtg 1500
gacagtggtcatggtgtatagtacaaatgtgttaa 1539

<210> SEQ ID NO 5
<211> LENGTH: 22
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic
<400> SEQUENCE: 5

Asp Phe Gly Pro Asp Trp Glu Asp Gly Asp Ser Tyr Asp Gly Ser Gly
1      5     10       15
Arg Gly Phe Phe Asp Phe
20

<210> SEQ ID NO 6
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic
<400> SEQUENCE: 6

Gly Ile Ile Pro Ile Phe Gly Thr Ser Asn Tyr Ala Gln Lys Phe Arg
1      5     10       15
Gly

<210> SEQ ID NO 7
<211> LENGTH: 5
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic
<400> SEQUENCE: 7

Met Tyr Gly Phe Aen
1      5

<210> SEQ ID NO 8
<211> LENGTH: 20
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic
<400> SEQUENCE: 8

Gln Gln Tyr Gly Thr Ser Pro Tyr Thr Phe Gly Gln Gly Gly Thr Lys Lue
1      5     10       15
Glu Ile Lys Arg
20

<210> SEQ ID NO 9
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic
<400> SEQUENCE: 9
Gly Ala Ser Thr Arg Ala Thr Gly Ile
1     5

SEQ ID NO 10
LENGTH: 13
ORIGIN: Artificial Sequence
OTHER INFORMATION: Synthetic

Arg Ala Ser Gln Ser Val Ser Ser Gly Ser Leu Ala Trp
1     5     10

SEQ ID NO 11
LENGTH: 261
ORIGIN: Artificial Sequence
OTHER INFORMATION: Synthetic

Met Lys Tyr Leu Leu Pro Thr Ala Ala Gly Leu Leu Leu Leu Ala
1     5     10     15

Ala Gln Pro Ala Met Ala Glu Val Gln Leu Leu Gln Ser Gly Ala
20    25    30

Glu Val Lys Pro Gly Ser Ser Val Gln Val Ser Cys Lys Ala Ser
35    40    45

Gly Gly Thr Phe Ser Met Tyr Gly Phe Asn Trp Val Arg Gln Ala Pro
50    55    60

Gly His Gly Leu Glu Trp Met Gly Gly Ile Pro Ile Phe Gly Thr
65    70    75    80

Ser Asn Tyr Ala Gln Lys Phe Arg Gly Arg Val Thr Phe Thr Ala Asp
85    90

Gln Ala Thr Ser Thr Ala Tyr Met Gln Leu Thr Asn Leu Arg Ser Asp
100   105   110

Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Phe Gly Pro Asp Trp Glu
115   120   125

Asp Gly Asp Ser Tyr Asp Gly Ser Tyr Gly Phe Phe Asp Phe Trp
130   135   140

Gly Gin Gly Thr Leu Val Thr Val Ser Ser Pro Gly Thr Lys Gly Pro
145   150   155   160

Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr
165   170    175

Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr
180   185   190

Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Val Gly His Thr Phe Pro
195   200   205

Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr
210   215   220

Val Pro Ser Ser Leu Gly Thr Gin Thr Tyr Ile Cys Asn Val Asp
225   230   235   240

His Lys Pro Ser Asn Thr Lys Val Asp Lys Val Glu Pro Lys Ser
245   250   255

Cys Asp Lys Thr Ser
<210> SEQ ID NO 13
<211> LENGTH: 1539
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 13

Gly Gly Gly Gly Ser
<210> SEQ ID NO 14
<211> LENGTH: 133
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 14

Met Ala Val Gln Leu Leu Glu Glu Ser Gly Ala Glu Val Lys Lys Pro
1   5   10   15
Gly Ser Ser Val Gln Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser
20  25   30
Met Tyr Gly Phe Asn Trp Val Arg Gln Ala Pro Gly His Gly Leu Glu
35  40   45
Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ser Asn Tyr Ala Gln
50  55   60
Lys Phe Arg Gly Arg Val Thr Phe Thr Ala Asp Gln Ala Thr Ser Thr
65  70   75   80
Ala Tyr Met Glu Leu Thr Asn Leu Arg Ser Asp Thr Ala Val Tyr
85  90   95
Tyr Cys Ala Arg Asp Phe Gly Pro Asp Trp Glu Asp Gly Asp Ser Tyr
100 105  110
Asp Gly Ser Gly Arg Gly Phe Phe Asp Phe Trp Gly Gly Gly Thr Leu
115 120  125
Val Thr Val Ser Ser
130

<210> SEQ ID NO 15
<211> LENGTH: 110
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 15

Asp Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Ala Gly
1   5   10   15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Gly
20  25   30
Ser Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
35  40  45
Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
50  55   60
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Gly Arg Leu Glu
65  70   75   80
Pro Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Thr Ser Pro
85  90   95
Tyr Thr Phe Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr
100 105  110
<400> SEQUENCE: 16
1  5  10  15
Gly Gly Gly Ser
20

<210> SEQ ID NO 17
<211> LENGTH: 30
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 17
1  5  10  15
20  25  30

<210> SEQ ID NO 18
<211> LENGTH: 40
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 18
1  5  10  15
20  25  30
Gly Gly Ser Gly Gly Gly Gly Ser
35  40

<210> SEQ ID NO 19
<211> LENGTH: 202
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 19
Met Asn Arg Gly Val Pro Phe Arg His Leu Leu Leu Val Leu Gln Leu
1  5  10  15
Ala Leu Leu Pro Ala Ala Thr Gin Gly Lys Val Val Leu Gly Lys
20  25  30
Lys Gin Asp Thr Val Glu Leu Thr Cys Thr Ala Ser Gin Lys Lys Lys Ser
35  40  45
Ile Gin Phe His Trp Lys Asn Ser Asn Gin Ile Lys Ile Leu Gly Asn
50  55  60
Gln Gly Ser Phe Leu Thr Lys Gly Pro Ser Lys Leu Asn Asp Arg Ala
65  70  75  80
Asp Ser Arg Arg Ser Leu Trp Asp Gin Gly Asn Phe Pro Leu Ile Ile
85  90  95
Lys Asn Leu Lys Ile Glu Asp Ser Asp Thr Tyr Ile Cys Glu Val Glu
100 105 110
Asp Gin Lys Glu Glu Val Gin Leu Leu Val Phe Gly Leu Thr Ala Asn
1.37. (canceled)

38. A method of selecting an antibody or antibody fragment with broadly neutralizing activity against HIV, comprising detecting an antibody or antibody fragment that specifically binds a CD4-inducible epitope on HIV Env that is enhanced by the binding of Env to a co-receptor for HIV, wherein the CD4-inducible epitope is distinct from the HIV co-receptor binding site on gp120.

39. The method of claim 38, wherein the antibody or antibody fragment is exposed to a complex comprising HIV gp120, CD4, and a co-receptor for HIV.

40. An antibody or antibody fragment produced by the method of claim 39.

41. A method of inhibiting entry of HIV into a cell, comprising administering to the cell an effective amount of an isolated antibody or antibody fragment that specifically binds a CD4-inducible epitope on HIV Env that is enhanced by the binding of Env to a co-receptor for HIV, wherein the CD4-inducible epitope is distinct from the HIV co-receptor binding site on gp120, thereby inhibiting entry of HIV into the cell.

42. The method of claim 41, wherein the cell is in a mammal that is susceptible to infection by HIV and wherein the isolated antibody or antibody fragment is administered to the mammal.

43. The method of claim 41, wherein the isolated antibody or antibody fragment is administered to the mammal by administering a nucleic acid encoding the isolated antibody or antibody fragment to the mammal.

44. The method of claim 42, wherein the mammal is a primate.

45. The method of claim 44, wherein the primate is a human.

46. The method of claim 41, wherein the HIV is HIV-1.

47. A method of inhibiting replication of HIV in a mammal that is susceptible to HIV infection, comprising administering to the mammal an effective amount of an isolated antibody or antibody fragment that specifically binds a CD4-inducible epitope on HIV Env that is enhanced by the binding of Env to a co-receptor for HIV, wherein the
CD4-inducible epitope is distinct from the HIV co-receptor binding site on gp120, thereby inhibiting replication of HIV in the mammal.

48. The method of claim 47, wherein the isolated antibody or antibody fragment is administered to the mammal by administering a nucleic acid encoding the isolated antibody or antibody fragment to the mammal.

49. The method of claim 47, wherein the mammal is a primate.

50. The method of claim 49, wherein the primate is a human.

51. The method of claim 47, wherein the HIV is HIV-1.

52. The method of claim 38, wherein the co-receptor is CCR5.

53. The method of claim 38, wherein the co-receptor is CXCR4.

54. The method of claim 41, wherein the antibody or antibody fragment comprises SEQ ID NO: 5 or SEQ ID NO: 8.

55. The method of claim 54, wherein the antibody or antibody fragment comprises SEQ ID NO: 5 and SEQ ID NO: 8.

56. The method of claim 54, wherein the antibody or antibody fragment comprises SEQ ID NO: 2 or SEQ ID NO: 3.

57. The method of claim 56, wherein the antibody or antibody fragment comprises SEQ ID NO: 2 and SEQ ID NO: 3.

58. The method of claim 47, wherein the antibody or antibody fragment comprises SEQ ID NO: 5 or SEQ ID NO: 8.

59. The method of claim 58, wherein the antibody or antibody fragment comprises SEQ ID NO: 5 and SEQ ID NO: 8.

60. The method of claim 58, wherein the antibody or antibody fragment comprises SEQ ID NO: 2 or SEQ ID NO: 3.

61. The method of claim 60, wherein the antibody or antibody fragment comprises SEQ ID NO: 2 and SEQ ID NO: 3.

62. A method of selecting an antibody or antibody fragment comprising selecting an antibody or antibody fragment that has a binding affinity for a complex comprising HIV gp120, CD4, and a co-receptor for HIV that is greater than its binding affinity for a complex comprising HIV gp120 and CD4 in the absence of the co-receptor for HIV.

63. The method of claim 62, wherein the method comprises selecting an antibody or antibody fragment for a binding affinity for a complex comprising HIV gp120, CD4, and a co-receptor for HIV that is at least about 1.2-fold greater than its affinity for a complex comprising HIV gp120 and CD4 in the absence of the co-receptor.

64. The method of claim 63, wherein the method comprises selecting an antibody or antibody fragment for a binding affinity for a complex comprising HIV gp120, CD4, and a co-receptor for HIV that is at least about 2-fold greater than its affinity for a complex comprising HIV gp120 and CD4 in the absence of the co-receptor.

* * * * *